Lyell Immunopharma (LYEL) Income towards Parent Company: 2020-2025
Historic Income towards Parent Company for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to -$34.0 million.
- Lyell Immunopharma's Income towards Parent Company rose 23.69% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.6 million, marking a year-over-year decrease of 71.61%. This contributed to the annual value of -$334.7 million for FY2024, which is 49.71% down from last year.
- Per Lyell Immunopharma's latest filing, its Income towards Parent Company stood at -$34.0 million for Q3 2025, which was up 22.52% from -$43.9 million recorded in Q2 2025.
- Lyell Immunopharma's 5-year Income towards Parent Company high stood at -$11.3 million for Q4 2022, and its period low was -$196.2 million during Q4 2024.
- In the last 3 years, Lyell Immunopharma's Income towards Parent Company had a median value of -$52.4 million in 2023 and averaged -$62.7 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first skyrocketed by 76.00% in 2022, then plummeted by 362.66% in 2023.
- Over the past 5 years, Lyell Immunopharma's Income towards Parent Company (Quarterly) stood at -$47.2 million in 2021, then soared by 76.00% to -$11.3 million in 2022, then crashed by 362.66% to -$52.4 million in 2023, then slumped by 274.31% to -$196.2 million in 2024, then climbed by 23.69% to -$34.0 million in 2025.
- Its Income towards Parent Company stands at -$34.0 million for Q3 2025, versus -$43.9 million for Q2 2025 and -$53.5 million for Q1 2025.